1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A

Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A

SSZSE:000403
9.63
CNY
+0.11
(+1.16%)
8.35BMarket Cap
Apr 23Next Earn
Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A
SZSE:000403
(Shenzhen Stock Exchange)

Recent

price

9.63

P/E

ratio

- -

div

yld

0.16%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.03
0.85
0.68
0.7
0.92
0.71
0.81
0.99
1.24
1.44
1.65
2.15
2.53
2.46
2.78
2.76
- -
Revenue per Share
0.06
0.07
0.05
0.1
0.23
0.11
0.07
0.03
0.12
0.25
0.29
0.43
0.62
0.65
0.78
0.44
- -
Basic EPS, GAAP
-0.05
0.1
-0.08
-0.1
0.01
0.02
-0.05
-0.08
0.12
0.24
0.24
0.09
0.15
0.32
-0.21
-0.58
- -
Free Cash Flow per Basic Share
0.01
0.01
0.01
0.02
0.02
0.01
0.04
0.01
0.03
0.23
0.28
0.01
0.05
0.07
0.28
0.29
0.02
Dividend per Share
0.38
0.37
0.43
0.43
0.61
0.72
0.77
0.8
0.92
1.16
1.51
6.64
7.21
7.8
8.34
8.51
8.48
Book Value per Share
0.12
0.15
0.22
0.28
0.51
0.62
0.67
0.7
0.82
1.05
1.37
3.62
4.18
4.76
5.26
5.45
5.4
Tangible Book Value per Share
530
544
689
686
532
703
692
692
692
636
637
917
950
947
956
953
997
Basic Weighted Avg Shares
546
461
470
478
489
500
561
685
860
916
1,050
1,972
2,405
2,329
2,655
2,633
- -
Sales/Revenue/Turnover
19.72
35.11
32.91
28.07
29.69
21.27
15.8
17.7
14.49
22.33
21.23
22.8
25.42
27.76
30.28
22.28
- -
Operating Margin (%)
34
34
30
30
46
48
49
48
49
46
47
116
126
145
131
142
- -
Depreciation Expense
29
41
33
70
123
78
50
22
80
160
186
391
587
612
745
419
- -
Net Income, GAAP
176.42
88.05
90.73
27.79
27.67
27.55
36.56
65.68
23.21
16.49
15.89
14.51
11.01
11.14
12.63
16.14
- -
Effective Tax Rate (%)
5.36
8.83
6.93
14.71
25.03
15.5
8.93
3.15
9.3
17.52
17.71
19.83
24.41
26.29
28.08
15.93
- -
Profit Margin (%)
-276
-139
-367
-339
-265
-260
-72
-11
87
339
227
1,827
2,088
2,504
2,622
2,593
2,628
Working Capital
12
- -
- -
92
72
47
24
23
9
9
42
21
82
218
322
206
390
LT Debt
274
283
288
352
459
525
527
542
622
802
967
6,328
6,861
7,422
7,918
8,081
8,050
Total Equity
1.17
1.15
0.88
6.68
10
6.25
4.72
3.69
8.9
17.06
16.14
10.01
8.57
8.1
9.29
5.05
- -
Return on Invested Capital (%)
9.04
14.88
12.07
20.36
23.13
14.29
9.94
4.82
13.13
20.93
18.12
10.21
8.72
8.2
9.16
4.97
- -
Return on Capital (%)
36.45
22.98
15.24
26.5
33.88
16.8
9.69
3.97
13.39
22.28
21.07
10.73
8.9
8.56
9.71
5.24
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
607
611
820
LT Borrowings
194
162
376
LT Finance Leases
12
14
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
950
950
950
Market Capitalization
13,011
12,298
8,354

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,721
3,550
3,915
Cash, Cash Equivalents & STI
1,025
699
1,072
Accounts Receivable, Net
930
843
754
Inventories
1,563
1,792
1,904
Total Current Liabilities
1,128
1,053
1,287
Payables & Accruals
- -
- -
- -
ST Debt
607
611
820
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
64.72%
115.96%
2.07%
Free Cash Flow
-38.55%
29.6%
176.19%
Net Income, GAAP
43.72%
28.54%
-43.75%
Sales/Revenue/Turnover
20.07%
23.95%
-0.83%
Total Cash Common Dividend
166.61%
110.6%
3.47%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
436
701
754
764
2,655
2025
375
612
- -
1,014
2,633
2026
343
487
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.22
0.23
0.21
0.78
2025
0.09
0.15
- -
0.07
0.44
2026
0.02
0.07
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.16
- -
0.11
0.28
2025
- -
0.27
- -
0.01
0.29
2026
- -
0.01
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the research, development, production, and sales of blood products in China. The company produces human serum albumin, human immunoglobulin, intravenous human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor; it also provides investment, consultation, and technology promotion services for pharmaceutical and biotechnology development projects as well as electronic product information consultation. Pacific Shuanglin Bio-pharmacy operates primarily in the biopharmaceutical industry, targeting healthcare providers and patients requiring plasma-derived therapies, with plasma collection stations across regions including Guangdong and Guangxi provinces. Founded in 1993 and headquartered in Taiyuan, Shanxi province, the company listed on the Shenzhen Stock Exchange in 1996, originally as Yichun Construction Machinery Co., Ltd., underwent multiple restructurings, and adopted its current name on March 30, 2021. In June 2025, China National Biotec Group Company Limited signed an acquisition framework agreement to purchase a 21.03% controlling stake from Gongqingcheng Shengbang Yinghao Investment Partnership, marking a significant ownership change and potential integration with Beijing Tiantan Biological Products.